Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Cyclooxygenase 2 is a key enzyme for inflammatory cytokine‐induced angiogenesis

View through CrossRef
Cyclooxygenasel (COX1) and COX2 mediate the rate‐limiting step in arachidonic acid me¬tabolism. Expression of COX2 mRNA and protein is often enhanced in various human cell types by inflam¬matory cytokines such as interleukin‐1β (IL‐1β) and tumor necrosis factor α (TNFα). IL‐1β enhanced ex¬pression of various prostanoids and this expression was blocked by COX2 selective inhibitors. IL‐1β markedly induced angiogenesis in vitro and in vivo, which was significantly inhibited by COX2 selective inhibitors but not by a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. In contrast, COX2 selective inhibitors only partially blocked VEGF‐induced angiogenesis. EP2, EP4 (prostaglandin E2 recep¬tors) agonists and thromboxane A2 (TXA2) receptor agonists induced angiogenesis in vitro and in vivo; IL‐1β‐induced angiogenesis was blocked by an EP4 antagonist and a TXA2 receptor antagonist. IL‐1β in¬duced much less angiogenesis in cornea of COX2 knockout mice than that of wild‐type mice. This is the first report that COX2 and some prostanoids play a key role in IL‐1β‐induced angiogenesis.—Kuwano, T., Nakao, S., Yamamoto, H., Tsuneyoshi, M., Yamamoto, T., Kuwano, M., Ono, M. Cyclooxygenase 2 is a keyenzyme for inflammatory cytokine‐induced angiogenesis. FASEB J. 18, 300–310 (2004)
Title: Cyclooxygenase 2 is a key enzyme for inflammatory cytokine‐induced angiogenesis
Description:
Cyclooxygenasel (COX1) and COX2 mediate the rate‐limiting step in arachidonic acid me¬tabolism.
Expression of COX2 mRNA and protein is often enhanced in various human cell types by inflam¬matory cytokines such as interleukin‐1β (IL‐1β) and tumor necrosis factor α (TNFα).
IL‐1β enhanced ex¬pression of various prostanoids and this expression was blocked by COX2 selective inhibitors.
IL‐1β markedly induced angiogenesis in vitro and in vivo, which was significantly inhibited by COX2 selective inhibitors but not by a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor.
In contrast, COX2 selective inhibitors only partially blocked VEGF‐induced angiogenesis.
EP2, EP4 (prostaglandin E2 recep¬tors) agonists and thromboxane A2 (TXA2) receptor agonists induced angiogenesis in vitro and in vivo; IL‐1β‐induced angiogenesis was blocked by an EP4 antagonist and a TXA2 receptor antagonist.
IL‐1β in¬duced much less angiogenesis in cornea of COX2 knockout mice than that of wild‐type mice.
This is the first report that COX2 and some prostanoids play a key role in IL‐1β‐induced angiogenesis.
—Kuwano, T.
, Nakao, S.
, Yamamoto, H.
, Tsuneyoshi, M.
, Yamamoto, T.
, Kuwano, M.
, Ono, M.
Cyclooxygenase 2 is a keyenzyme for inflammatory cytokine‐induced angiogenesis.
FASEB J.
18, 300–310 (2004).

Related Results

Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Abstract Angiogenesis and inflammation are two closely related processes and inhibition of angiogenesis can ameliorate inflammatory diseases by reducing the recruitm...
Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat Kidney
Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat Kidney
In the rat isolated perfused kidney, arachidonic acid elicits cyclooxygenase-dependent vasoconstriction through activation of PGH 2 /TxA 2 ...
Comprehensive Analysis of Angiogenesis Subtype of Squamous Cell Carcinoma
Comprehensive Analysis of Angiogenesis Subtype of Squamous Cell Carcinoma
Abstract Background: Squamous cell carcinoma (SCC) is a disease with distinct management complexities as it displays a remarkably heterogeneous molecular subtype. However, ...
Comprehensive Analysis of Angiogenesis subtype of Squamous Cell Carcinoma
Comprehensive Analysis of Angiogenesis subtype of Squamous Cell Carcinoma
Abstract Background: Squamous cell carcinoma (SCC) is a disease with distinct management complexities as it displays a remarkably heterogeneous molecular subtype. However, ...
Docking and Structural Modification of Flavonoid Derivative Compounds as Cycloxygenas-2 Enzyme Inhibitors
Docking and Structural Modification of Flavonoid Derivative Compounds as Cycloxygenas-2 Enzyme Inhibitors
Seven flavonoid compounds have the activity of inhibiting the cyclooxygenase-2 (COX-2) enzyme, thus providing an anti-inflammatory effect. Molecular docking analysis is needed to d...
Abstract 3208: Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
Abstract 3208: Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
Abstract Angiogenesis inhibition has become a mainstay of oncology despite having fallen short of its early promise. As originally envisioned, angiogenesis inhibitio...
Advancements in diagnosis and treatment of Adenomyosis
Advancements in diagnosis and treatment of Adenomyosis
In this thesis, we aimed to study how we can improve the diagnosing of adenomyosis by imaging the uterus in part I, especially using ultrasound and considering the assessment of th...
Neuregulin‐4 Limits Pro‐Inflammatory Cytokine Production in Macrophages
Neuregulin‐4 Limits Pro‐Inflammatory Cytokine Production in Macrophages
BackgroundPro‐inflammatory macrophages are critical mediators of intestinal inflammation. Over‐aggressive responses from these cells, including elevated cytokine release and prolon...

Back to Top